Maze Therapeutics (MAZE) Total Non-Current Liabilities (2024 - 2026)

Maze Therapeutics has disclosed Total Non-Current Liabilities across 3 years of filings, most recently posting $77.6 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $77.6 million, up 95.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $77.6 million (up 95.19% YoY), and the FY2025 annual result was $41.1 million, down 3.75% from the prior year.
• Total Non-Current Liabilities came in at $77.6 million for Q1 2026 at Maze Therapeutics, up from $41.1 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $77.6 million in Q1 2026 to a low of $39.8 million in Q1 2025.
• The 3-year median for Total Non-Current Liabilities is $41.3 million (2025), against an average of $47.1 million.
• Across the five-year window, Total Non-Current Liabilities fell 3.75% in 2025 and surged 95.19% in 2026, its largest moves.
• Maze Therapeutics' Total Non-Current Liabilities stood at $42.7 million in 2024, then fell by 3.75% to $41.1 million in 2025, then jumped by 89.01% to $77.6 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $77.6 million (Q1 2026), $41.1 million (Q4 2025), and $41.5 million (Q3 2025), per Business Quant data.